Hutchmed China kicks off phase three stage of pancreatic cancer trial
(Alliance News) - Hutchmed China Ltd on Monday said it has started the phase three part of a trial evaluating surufatinib and camrelizumab for the treatment of pancreatic cancer in China. Read More